Physician profile
Ruth M Spillerman
NPI 1578567566
$2,136.00
in general payments reported to CMS, 2019-2025
22 companies · $383 in 2025
The $383 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $213 · 2021: $198 · 2022: $407 · 2023: $353 · 2024: $315 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $288.06 | 2022-2025 | Azstarys, Azstarys |
| Sanofi Pasteur INC. | $214.16 | 2019-2024 | |
| Glaxosmithkline, LLC. | $194.90 | 2019-2025 | Bexsero, Penmenvy |
| Merck Sharp & Dohme LLC | $170.64 | 2020-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Supernus Pharmaceuticals, INC. | $160.50 | 2021-2024 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $142.26 | 2025 | Jornay Pm |
| Pfizer INC. | $136.83 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.96 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $111.79 | 2019-2024 | Jornay Pm |
| Cranial Technologies, INC | $111.77 | 2020-2025 | Doc Band |
| Kaleo, INC. | $90.31 | 2021-2022 | |
| Tris Pharma INC | $86.34 | 2019-2021 | |
| Seqirus USA INC | $82.55 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Sanofi-Aventis U.S. LLC | $49.81 | 2024-2025 | |
| Adlon Therapeutics L.P. | $46.46 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $42.72 | 2019 | |
| Verrica Pharmaceuticals INC. | $16.56 | 2025 | Ycanth |
| Neurelis, INC. | $16.26 | 2022 | |
| Biofire Diagnostics, LLC | $16.13 | 2019 | |
| Neos Therapeutics, Lp | $15.95 | 2022 | |
| Mission Pharmacal Company | $14.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Spillerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.